Investigating how non-exudative type 1 macular neovascularization affects age-related macular degeneration progression
The Impact of Non-Exudative Type 1 Macular Neovascularization (MNV) on Age-related Macular Degeneration (AMD) Progression
This study is looking at how a specific type of eye growth called non-exudative type 1 macular neovascularization might help protect vision in people with age-related macular degeneration, and it could lead to better ways to manage this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10873833 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of non-exudative type 1 macular neovascularization (MNV) in the progression of age-related macular degeneration (AMD), a leading cause of vision loss. The study aims to determine if this specific type of MNV can help preserve retinal function and structure in patients with AMD. Using advanced imaging techniques and sensitivity testing, researchers will assess the impact of non-exudative MNV on surrounding retinal tissues. This could lead to new insights into AMD management and treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with age-related macular degeneration who exhibit non-exudative type 1 macular neovascularization.
Not a fit: Patients with exudative age-related macular degeneration or those without any form of macular neovascularization may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new strategies for preserving vision in patients with age-related macular degeneration.
How similar studies have performed: While there is emerging evidence regarding the protective effects of non-exudative MNV, this specific approach is relatively novel and has not been extensively tested in prior research.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Fleckenstein, Monika — University of Utah
- Study coordinator: Fleckenstein, Monika
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.